⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRVO News
CervoMed Inc. Common Stock
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
globenewswire.com
CRVO
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
globenewswire.com
CRVO
Wall Street Chases the Next Big Breakout
globenewswire.com
CRVO
NTHI
SPCX
WULF
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
globenewswire.com
NTHI
CRVO
EWTX